Sanofi
Coverage of Sanofi in the Nexus archive.
- STAT+: European antitrust regulators probe Sanofi for allegedly disparaging a rival flu vaccine
The European Commission is investigating Sanofi for allegedly violating antitrust rules by running a misleading campaign that disparages CSL Seqirus's Fluad vaccine, portraying it as inferior to Sanofi's Efluelda vaccine. The campaign targeted healthcare professionals in Germany and France, where Sanofi holds a dominant market position, and contradicted national vaccine recommendations in several EU member states.
- EU hits France's Sanofi with flu vaccine antitrust probe
The European Union has initiated an antitrust probe against France's Sanofi, a drugmaker, over its flu vaccine. The article notes Sanofi's logo at a Paris technology fair.
- Brussels launches antitrust probe into French drugmaker Sanofi
Brussels has launched an antitrust probe into French drugmaker Sanofi, investigating whether the company conducted a misleading campaign against a rival flu vaccine manufacturer. The competition watchdog is examining potential anticompetitive practices related to flu vaccines.
- STAT+: Sanofi names new R&D head as it tries to jumpstart pipeline
Sanofi appointed Paulo Fontoura as global head of R&D to rejuvenate its pipeline under new CEO Belén Garijo. Fontoura, a neurologist with prior roles at Xaira Therapeutics and Roche, replaces Houman Ashrafian, who is leaving for an external opportunity.
- Gesundheitsreform: Die Pharmaindustrie und der Streit ums Sparen
The article discusses the tension between Germany's health reform and the pharmaceutical industry's competitiveness, focusing on Sanofi's Heidrun Irschik-Hadjieff's warnings about the impact of a proposed dynamic manufacturer discount on future investments. It also touches on digital sovereignty debates in Europe and the role of the 'Power & Policy' podcast in analyzing economic policy decisions.
- STAT+: FDA approves Sanofi diabetes drug for children with stage 3 diabetes
The FDA approved Sanofi's teplizumab for children aged 8 and older with stage 3 diabetes. The drug underwent a speedy review program but the agency missed its decision deadline of April 21. Sanofi requested to withdraw the drug from the program after Tracy Beth Høeg, a former top drug regulator, disagreed with a staff approval decision.
- STAT+: Hope for Kendall Square’s lab market
Sanofi halted a Phase 3 study of its drug riliprubart due to lack of efficacy, while Parabilis Medicines raised $670 million in a record biotech IPO. European countries face conflicts over drug-pricing policies amid budget strains and U.S. pressure.
- STAT+: Pharmalittle: We’re reading about Sanofi and an FDA voucher, FDA rethinking a rejection, and more
Sanofi has asked the FDA to pull its type 1 diabetes drug from a speedy review program after a staff decision to approve the drug was disagreed with by the acting Center for Drug Evaluation and Research Director. An experimental drug from Revolution Medicines has shown promise in clinical trials for advanced pancreas cancer. The FDA is rethinking its approach to drug approvals.
- STAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
Sanofi has asked the FDA to pull its type 1 diabetes drug, teplizumab, out of a speedy drug review program after a dispute over the approval decision. The agency missed its goal date of April 21 to deliver a decision to Sanofi. The dispute involved acting Center for Drug Evaluation and Research director Tracy Beth Høeg.